Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with recurrent
malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor.